Hemostemix Drives Social Media Awareness of Its Regenerative Medicine Treatments
Hemostemix (TSXV: HEM) (OTC: HMTXF) has launched a comprehensive social media campaign across Instagram, Facebook, LinkedIn, YouTube, and X to showcase patient success stories and educate about their regenerative medicine treatments. The company's flagship treatment, ACP-01, derived from patients' own blood and cultured in their serum, has demonstrated significant clinical results:
In dilated cardiomyopathy patients, cardiac function improved by up to 47.1% after one treatment, with notable improvements in severe cases. For Chronic Limb Threatening Ischemia (CLTI) patients, 83% experienced healing of ulcers and resolution of ischemic rest pain in follow-ups up to 4.5 years. Ulcer size decreased significantly from 1.46 cm² to 0.48 mm² within three months.
Hemostemix (TSXV: HEM) (OTC: HMTXF) ha lanciato una campagna di social media completa su Instagram, Facebook, LinkedIn, YouTube e X per mostrare le storie di successo dei pazienti e informare sulle terapie di medicina rigenerativa. Il trattamento di punta dell'azienda, ACP-01, derivato dal sangue dei pazienti e coltivato nel loro siero, ha dimostrato risultati clinici significativi:
Nei pazienti con cardiomiopatia dilatativa, la funzione cardiaca è migliorata fino al 47,1% dopo un trattamento, con miglioramenti notevoli nei casi più gravi. Per i pazienti con ischemia cronica agli arti minacciata (CLTI), l'83% ha mostrato la guarigione delle ulcere e la risoluzione del dolore ischemico in follow-up fino a 4,5 anni. La dimensione delle ulcere è diminuita significativamente da 1,46 cm² a 0,48 mm² entro tre mesi.
Hemostemix (TSXV: HEM) (OTC: HMTXF) ha lanzado una campaña integral en redes sociales a través de Instagram, Facebook, LinkedIn, YouTube y X para mostrar historias de éxito de pacientes y educar sobre sus tratamientos de medicina regenerativa. El tratamiento principal de la empresa, ACP-01, derivado de la sangre propia de los pacientes y cultivado en su suero, ha demostrado resultados clínicos significativos:
En pacientes con cardiomiopatía dilatada, la función cardíaca mejoró hasta en un 47,1% después de un tratamiento, con notables mejoras en los casos severos. Para los pacientes con isquemia crónica amenazante para las extremidades (CLTI), el 83% experimentó la curación de úlceras y la resolución del dolor isquémico en seguimientos de hasta 4,5 años. El tamaño de las úlceras disminuyó significativamente de 1,46 cm² a 0,48 mm² en tres meses.
헤모스테믹스 (TSXV: HEM) (OTC: HMTXF)는 인스타그램, 페이스북, 링크드인, 유튜브, X를 통해 환자 성공 사례를 보여주고 자가 재생 의학 치료에 대해 교육하기 위한 포괄적인 소셜 미디어 캠페인을 시작했습니다. 회사의 주력 치료제인 ACP-01은 환자 자신의 혈액에서 유래하고 그들의 혈청에서 배양된 것으로, 성과가 두드러진 임상 결과를 보여주었습니다:
확장형 심근병증 환자의 경우, 치료 후 심장 기능이 최대 47.1% 개선되었으며, 중증 환자에서 특히 주목할 만한 개선이 있었습니다. 만성 사지 위협 허혈(CLTI) 환자의 경우, 83%가 궤양이 치유되고 4.5년에 걸친 추적 조사에서 허혈성 안정 통증이 해결되었습니다. 궤양 크기는 1.46 cm²에서 0.48 mm²로 세 달 이내에 크게 감소했습니다.
Hemostemix (TSXV: HEM) (OTC: HMTXF) a lancé une campagne de médias sociaux complète sur Instagram, Facebook, LinkedIn, YouTube et X pour mettre en avant les histoires de réussite des patients et éduquer sur leurs traitements en médecine régénérative. Le traitement phare de l'entreprise, ACP-01, dérivé du sang des patients et cultivé dans leur sérum, a montré des résultats cliniques significatifs :
Chez les patients atteints de cardiomyopathie dilatée, la fonction cardiaque s'est améliorée jusqu'à 47,1 % après un traitement, avec des améliorations notables dans les cas graves. Pour les patients atteints d'ischémie chronique menaçant les membres (CLTI), 83 % ont connu la guérison des ulcères et la résolution de la douleur ischémique au repos lors des suivi allant jusqu'à 4,5 ans. La taille des ulcères a diminué de manière significative, passant de 1,46 cm² à 0,48 mm² en trois mois.
Hemostemix (TSXV: HEM) (OTC: HMTXF) hat eine umfassende Social-Media-Kampagne auf Instagram, Facebook, LinkedIn, YouTube und X gestartet, um die Erfolgsgeschichten von Patienten zu präsentieren und über ihre regenerativen Medizinbehandlungen aufzuklären. Die Hauptbehandlung des Unternehmens, ACP-01, die aus dem eigenen Blut der Patienten gewonnen und in ihrem Serum kultiviert wird, hat bedeutende klinische Ergebnisse gezeigt:
Bei Patienten mit dilatativer Kardiomyopathie verbesserte sich die Herzfunktion nach einer Behandlung um bis zu 47,1%, wobei in schweren Fällen bemerkenswerte Verbesserungen auftraten. Bei Patienten mit chronischer beinbedrohlicher Ischämie (CLTI erlebten 83% die Heilung von Geschwüren und die Lösung von iskämischen Ruhe-Schmerzen in Follow-ups von bis zu 4,5 Jahren. Die Größe der Geschwüre verringerte sich innerhalb von drei Monaten signifikant von 1,46 cm² auf 0,48 mm².
- None.
- None.
Hemostemix is revolutionizing how individuals think about their own regenerative medicine treatments. With social media, the company is educating about its treatments and advancements.
Calgary, Alberta--(Newsfile Corp. - December 17, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the launch of its social media campaign across Instagram, Facebook, LinkedIn, YouTube, and X. This campaign aims to share patient success stories, connect with individuals seeking safe and innovative treatments for no-option cardiovascular diseases, and educate the public about Hemostemix as an investment opportunity.
Follow Hemostemix:
- Instagram: https://www.instagram.com/hemostemix.inc?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==
- Facebook: https://www.facebook.com/profile.php?id=100087329604596
- LinkedIn: https://www.linkedin.com/company/3212019/
- YouTube:https://www.youtube.com/@hemostemix3830
- X: @heartrepairguy
Innovating Health and Restoring Quality of Life
"Our campaign provides knowledge about the patient's own regenerative medicine, describing how ACP-01 significantly improves a cardiovascular patient's condition and quality of life," said Thomas Smeenk, CEO.
ACP-01, sourced from the patient's blood and cultured in the patient's serum, is proven to be safe and statistically significant. For example:
- In dilated cardiomyopathy patients, cardiac function as measured by left ventricle ejection fraction percent (LVEF%) increased by up to
47.1% following one treatment (Stem Cell Research & Therapy, November 2023), with the most marked improvements observed in patients with severe dilated cardiomyopathy (LVEF% <20% ).
Addressing Chronic Limb Threatening Ischemia (CLTI): As compared to the five-year mortality rate of
83% of patients followed for up to 4.5 years experienced healing of ulcers and resolution of ischemic rest pain. Additionally, the Company published that ulcer size decreased significantly in the treated group from a mean of 1.46 cm² to 0.48 mm², p = 0.01 within three months (Journal of Biomedical Research & Environmental Science, February 2024).
About Hemostemix
Founded in 2003, Hemostemix is a clinical-stage biotechnology company and winner of the World Economic Forum Technology Pioneer Award. The Company has developed and patented a blood-based stem cell therapeutics platform that includes angiogenic cell precursors (ACP), neuronal cell precursors (NCP), and cardiomyocyte cell precursors (CCP). These treatments are designed to transform outcomes for patients with severe cardiovascular and nervous system conditions.
For more information, visit www.hemostemix.com.
For further information, please contact:
Thomas Smeenk, President & CEO
Email: tsmeenk@hemostemix.com
Phone: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Program. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/234146
FAQ
What clinical results has HMTXF's ACP-01 treatment shown for cardiomyopathy patients?
What are the success rates of HMTXF's treatment for CLTI patients?
Which social media platforms is HMTXF using for its new awareness campaign?
How does HMTXF's ACP-01 treatment work?
What is the comparative advantage of HMTXF's CLTI treatment versus standard outcomes?
